3-nitropropionic acid has been researched along with Disease Models, Animal in 228 studies
3-nitropropionic acid: succinate dehydrogenase inactivator; biosynthesized by FABACEAE plants from ASPARAGINE
3-nitropropanoic acid : A C-nitro compound that is propanoic acid in which one of the methyl hydrogens has been replaced by a nitro group.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The toxin 3-Nitropropionic acid (3-NP) can induce neuropathologies in the mice striatum and nigra substance, including excitotoxicity, neuroinflammation, and extensive neuronal atrophy, characterized by progressive motor dysfunction, dystonia, and memory loss, mimicking those observed in humans." | 8.02 | Combined treatment with C16 peptide and angiopoietin-1 confers neuroprotection and reduces inflammation in 3-nitropropionic acid-induced dystonia mice. ( Cai, HY; Fu, XX; Han, S; Jiang, H, 2021) |
| "Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by autonomic failure, parkinsonism, cerebellar ataxia, and oligodendrocytic accumulation of alpha-synuclein (alphasyn)." | 7.75 | Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. ( Adame, A; Inglis, C; Lee, PH; Mante, M; Masliah, E; Rockenstein, E; Stefanova, N; Ubhi, K; Wenning, GK, 2009) |
| "The role of adenosine A1 receptors in the activity of drugs and substances protecting against seizures evoked by mitochondrial toxin, 3-nitropropionic acid (3-NPA) was studied in mice." | 7.73 | Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice. ( Urbańska, EM; Wielosz, M; Zuchora, B, 2005) |
| "Intrastriatal injection of 3-nitropropionic acid results in secondary excitotoxic local damage and retrograde neuronal cell loss in substantia nigra pars compacta, thus mimicking salient features of striatonigral degeneration, the core pathology underlying Parkinsonism associated with multiple system atrophy." | 7.71 | No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). ( Jellinger, K; Poewe, W; Puschban, Z; Scherfler, C; Seppi, K; Waldner, R; Wenning, GK, 2001) |
| "Reactive astrocytosis seems to be strongly implicated in the development and maintenance of inflammatory and neurodegenerative disorders." | 5.36 | Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. ( Bianco, MR; Cirillo, G; Maggio, N; Papa, M; Sellitti, S; Vollono, C, 2010) |
| "We propose that the appearance of dystonia after 3NP intoxication following dopaminergic striatal denervation is the key symptom predictive of the loss of dopaminergic response." | 5.31 | Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. ( Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK, 2002) |
| " The toxin 3-Nitropropionic acid (3-NP) can induce neuropathologies in the mice striatum and nigra substance, including excitotoxicity, neuroinflammation, and extensive neuronal atrophy, characterized by progressive motor dysfunction, dystonia, and memory loss, mimicking those observed in humans." | 4.02 | Combined treatment with C16 peptide and angiopoietin-1 confers neuroprotection and reduces inflammation in 3-nitropropionic acid-induced dystonia mice. ( Cai, HY; Fu, XX; Han, S; Jiang, H, 2021) |
| "This study was designed to evaluate the effects of bis selenide on Huntington disease (HD)-like signs induced by 3-nitropropionic acid (3-NP) in rats." | 3.79 | Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats. ( Bortolatto, CF; Chagas, PM; Jesse, CR; Nogueira, CW; Wilhelm, EA, 2013) |
| "Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by autonomic failure, parkinsonism, cerebellar ataxia, and oligodendrocytic accumulation of alpha-synuclein (alphasyn)." | 3.75 | Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. ( Adame, A; Inglis, C; Lee, PH; Mante, M; Masliah, E; Rockenstein, E; Stefanova, N; Ubhi, K; Wenning, GK, 2009) |
| "The role of adenosine A1 receptors in the activity of drugs and substances protecting against seizures evoked by mitochondrial toxin, 3-nitropropionic acid (3-NPA) was studied in mice." | 3.73 | Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice. ( Urbańska, EM; Wielosz, M; Zuchora, B, 2005) |
| " The injections of MitoTracker Red CM-H(2)XRos revealed generation of mitochondrial free radicals primarily in vulnerable neurons following focal cerebral ischemia as well as administration of Fe(2+) or 3-nitropropionic acid." | 3.71 | Analysis of mitochondrial free radical generation in animal models of neuronal disease. ( Gwag, BJ; Kim, DY; Won, SJ, 2002) |
| "The 3-nitropropionic acid animal model is a model where excitotoxicity, mitochondrial dysfunction and oxidative stress, mechanisms common to various neurodegenerative diseases, are involved." | 3.71 | Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. ( Angevaren, M; Appels, M; de Bruijn, C; de Vente, J; Prickaerts, J; Steinbusch, HW; Teunissen, CE, 2001) |
| "Intrastriatal injection of 3-nitropropionic acid results in secondary excitotoxic local damage and retrograde neuronal cell loss in substantia nigra pars compacta, thus mimicking salient features of striatonigral degeneration, the core pathology underlying Parkinsonism associated with multiple system atrophy." | 3.71 | No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). ( Jellinger, K; Poewe, W; Puschban, Z; Scherfler, C; Seppi, K; Waldner, R; Wenning, GK, 2001) |
| " Remarkably, in a rat model of Huntington's disease generated by subcutaneous infusion of the mitochondrial inhibitor 3-nitropropionic acid (3NP), we have observed that an acute treatment with ADAC (100 microg x kg(-1) x d(-1)) not only strongly reduces the size of the striatal lesion (-40%) and the remaining ongoing striatal degeneration (-30%), but also prevents the development of severe dystonia of hindlimbs." | 3.71 | The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. ( Bantubungi, K; Blum, D; d'Alcantara, P; Galas, MC; Gall, D; Schiffmann, SN, 2002) |
| "Ellagic acid (EA) is a naturally derived polyphenol acknowledged for potent neuroprotective abilities that enabled its significance amongst popular brain tonics." | 1.62 | Ellagic acid prevents 3-nitropropionic acid induced symptoms of Huntington's disease. ( Bansal, N; Kumar, M; Sharma, P, 2021) |
| " However, their toxic properties have yet to be explored in the nematode Caenorhabditis elegans (C." | 1.48 | Comparison of the Toxic Effects of Quinolinic Acid and 3-Nitropropionic Acid in C. elegans: Involvement of the SKN-1 Pathway. ( Aguilera-González, MF; Aschner, M; Avila, DS; Colonnello, A; de Lima, ME; García-Contreras, R; Kotlar, I; Ortíz-Plata, A; Santamaría, A; Soares, FAA, 2018) |
| "Tauopathies are a group of disorders in which the cytosolic protein tau aggregates and accumulates in cells within the brain, resulting in neurodegeneration." | 1.46 | Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. ( Boxer, AL; Braunstein, J; Cairns, NJ; Finn, MB; Fogelman, I; Gallardo, G; Holtzman, DM; Hu, Y; Jiang, H; Kerwin, DR; Keyser, J; Knapik, SS; Miller, BL; Patel, TK; Robinson, G; Roh, J; Schindler, S; Stewart, F; Ulrich, JD; Verghese, PB; West, T; Yanamandra, K, 2017) |
| "Selegiline was intraperitoneally injected at doses 2." | 1.46 | Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats. ( Khalifa, AE; Tadros, MG; Wahdan, SA, 2017) |
| "Treatment with moxonidine, NDDCT and TBZ significantly attenuated 3-NPA induced reduction in body weight, locomotor activity, grip strength, anxiety as well as impaired learning and memory." | 1.40 | Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. ( Gupta, S; Sharma, B, 2014) |
| " Dose-response of the cochlear cells to 3-nitropropionic acid was analyzed in vitro." | 1.39 | Mitochondria toxin-induced acute cochlear cell death indicates cellular activity-correlated energy consumption. ( Poe, D; Pyykkö, I; Yang, S; Zhai, S; Zhang, W; Zhang, Y; Zou, J, 2013) |
| "Although the mutated protein causing Huntington's disease (HD) is expressed throughout the body, the major pathology of HD is localized to the striatum of the brain." | 1.39 | Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease. ( Mealer, RG; Snyder, SH; Subramaniam, S, 2013) |
| "Pretreatment with hesperidin (100 mg/kg) ahead of 3-NP prevented any changes of locomotor activity or PPI response, slightly increased cortical, striatal and hippocampal MDA levels by 10% and reduced respective catalase activity by 22%, 20% and 5%." | 1.38 | Potential neuroprotective effects of hesperidin on 3-nitropropionic acid-induced neurotoxicity in rats. ( Abdel-Tawab, AM; Khalifa, AE; Menze, ET; Tadros, MG, 2012) |
| "Treatment with naringin ameliorated the reduced glutathione/oxidized glutathione ratio with concomitant decrease in the levels of hydroxyl radical, hydroperoxide and nitrite in 3-NP-induced rats." | 1.38 | Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway. ( Gopinath, K; Sudhandiran, G, 2012) |
| "Machado-Joseph disease (MJD), also known as Spinocerebellar Ataxia type 3, is an inherited dominant autosomal neurodegenerative disorder." | 1.38 | Compromised mitochondrial complex II in models of Machado-Joseph disease. ( Laço, MN; Oliveira, CR; Paulson, HL; Rego, AC, 2012) |
| " Our data suggest that the two studied toxic models (QA and 3-NP) or the combined model (QA plus 3-NP) can generate complex patterns of damage, which involve metabolic compromise, ROS formation, and oxidative stress." | 1.38 | Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro. ( Colle, D; Farina, M; Hartwig, JM; Soares, FA, 2012) |
| "Multiple system atrophy is a rapidly progressive neurodegenerative disorder with a markedly reduced life expectancy." | 1.37 | Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. ( Köllensperger, M; Krismer, F; Pallua, A; Poewe, W; Stefanova, N; Wenning, GK, 2011) |
| "Reactive astrocytosis seems to be strongly implicated in the development and maintenance of inflammatory and neurodegenerative disorders." | 1.36 | Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. ( Bianco, MR; Cirillo, G; Maggio, N; Papa, M; Sellitti, S; Vollono, C, 2010) |
| "Sesamol pre-treatment restored oxidative defence possibly by its free radical scavenging activity as compared to the 3NP-treated group." | 1.36 | Protective effect of sesamol against 3-nitropropionic acid-induced cognitive dysfunction and altered glutathione redox balance in rats. ( Kalonia, H; Kumar, A; Kumar, P, 2010) |
| "Quinolinic acid (QUIN) was used as a typical excitotoxic/pro-oxidant inducer, 3-nitropropionic acid (3-NP) was employed as a mitochondrial function inhibitor, and their combination (QUIN + 3-NP) was also evaluated in in vitro studies." | 1.36 | Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine. ( Elinos-Calderón, D; Galván-Arzate, S; Maldonado, PD; Pedraza-Chaverrí, J; Pérez-De La Cruz, V; Robledo-Arratia, Y; Santamaría, A, 2010) |
| " Chronic administration of W." | 1.35 | Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease. ( Kumar, A; Kumar, P, 2009) |
| "Huntington's disease is an incurable, adult-onset, dominantly inherited neurodegenerative disease." | 1.35 | Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats. ( Akula, KK; Dhir, A; Kulkarni, SK, 2008) |
| "Atorvastatin-treated rats showed fewer neurologic deficits than control animals as measured at day 3-5." | 1.35 | Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways. ( Chu, K; Han, Z; Hong, NH; Im, WS; Jung, KH; Kang, L; Kim, M; Kim, MW; Lee, ST; Park, JE, 2008) |
| "However, its potential in Huntington's disease (HD) models characterized by calpain-dependent degeneration and inflammation has not been investigated." | 1.33 | Minocycline in phenotypic models of Huntington's disease. ( Bantubungi, K; Blum, D; Brotchi, J; Brouillet, E; Chtarto, A; Déglon, N; Galas, MC; Greco, A; Jacquard, C; Levivier, M; Minghetti, L; Pintor, A; Popoli, P; Schiffmann, SN; Tai, K; Tenenbaum, L, 2005) |
| "In summary, arvanil does alleviate hyperkinesia typical of HD, although it also affects locomotion in normal rats." | 1.33 | Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. ( de Lago, E; Di Marzo, V; Fernández-Ruiz, J; Ramos, JA; Urbani, P, 2005) |
| "An experimental animal model of Huntington's disease (HD) phenotype was induced using the mycotoxin 3-nitropropionic acid (3-NP) and was well characterized behaviorally, neurochemically, morphometrically and histologically." | 1.33 | Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. ( Abdel-Naim, AB; Arafa, HM; Khalifa, AE; Tadros, MG, 2005) |
| " In astrocyte cultures, the toxic effects of 3-NPA were associated with corresponding increases in the NO(2)(-) level, and this toxicity was attenuated by hemoglobin (Hb; 20 microM), which quenches NO." | 1.33 | Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats. ( Baba, H; Deshpande, SB; Hida, H; Masuda, T; Nishino, H; Takei-Io, N, 2006) |
| "Huntington's disease has an increase in the activated calpain, which is enhanced by the NMDA receptor activation." | 1.33 | Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. ( Chu, K; Jung, KH; Kang, L; Kim, M; Ko, SY; Lee, ST; Park, JE, 2006) |
| "Striatal gliosis induced by 3-NP treatment was prevented by (+/-)-huprine Y pretreatment, as demonstrated by the attenuation of both the increase in [(3)H]PK 11195 specific binding indicative of microgliosis and the expression of hsp27 kDa, a chaperone expressed mainly in astrocytes." | 1.32 | Neuroprotective effects of (+/-)-huprine Y on in vitro and in vivo models of excitoxicity damage. ( Camins, A; Camps, P; Canudas, AM; Jiménez, A; Muñoz-Torrero, D; Pallàs, M; Pubill, D; Sureda, FX; Verdaguer, E, 2003) |
| "Striatal cell death in Huntington's Disease (HD) may involve mitochondrial defects, NMDA-mediated excitotoxicity, and activation of death effector proteases such as caspases and calpain." | 1.32 | Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. ( Bizat, N; Boyer, F; Brouillet, E; Créminon, C; Escartin, C; Hantraye, P; Hermel, JM; Jacquard, C; Kajewski, S; Ouary, S, 2003) |
| "The precise cause of neuronal death in Huntington's disease (HD) is unknown." | 1.32 | Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. ( Beesen, A; Ferrante, RJ; Hersch, SM; Kowall, NW; Kubilus, JK; Lee, J; Luthi-Carter, R; Ratan, RR; Ryu, H; Smith, K; Zucker, B, 2003) |
| "An important aspect of Huntington's disease (HD) pathogenesis which may have important therapeutic implications is that the cellular events leading to cell death may be different in cortical and striatal neurons." | 1.32 | Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. ( Bantubungi, K; Bizat, N; Blum, D; Brouillet, E; Cuvelier, L; Galas, MC; Schiffmann, SN, 2004) |
| "Age of onset of Huntington's disease (HD) statistically correlates with the length of expanded CAG repeats in the IT15 gene." | 1.32 | Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history. ( Centelles, L; Diguet, E; Fernagut, PO; Mulle, C; Normand, E; Tison, F, 2004) |
| "To investigate the effects of time interval and cumulative dosage of repetitive mild cellular hypoxia on shape of neurodegeneration and neuroprotection in mice, population spike amplitude (PSA) was measured during hypoxia and posthypoxic recovery in hippocampal slices from untreated control and mice pretreated in vivo with a single or repeatedly intraperitoneal injection of 3-nitropropionate (3-NP)." | 1.31 | Increased neuronal hypoxic tolerance induced by repetitive chemical hypoxia. ( Li, H; Liu, C; Sun, S, 2002) |
| "We propose that the appearance of dystonia after 3NP intoxication following dopaminergic striatal denervation is the key symptom predictive of the loss of dopaminergic response." | 1.31 | Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. ( Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK, 2002) |
| "We developed a primate model of striatonigral degeneration (SND), the neuropathology underlying levodopa-unresponsive parkinsonism associated with multiple systemic atrophy (MSA-P), by sequential systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3-nitropropionic acid (3NP) in a Macaca fascicularis monkey." | 1.31 | Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. ( Aubert, I; Bezard, E; Fernagut, PO; Ghorayeb, I; Poewe, W; Tison, F; Wenning, GK, 2000) |
| "Neuronal loss in Huntington's disease (HD) is seen first in the neostriatum." | 1.31 | Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity. ( Hickey, MA; Morton, AJ, 2000) |
| "The effects of a previous long-term administration of the mitochondrial toxin 3-nitropropionic acid were studied on an animal model of tardive dyskinesia, i." | 1.31 | The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats. ( Abilio, VC; Araujo, CC; Bergamo, M; Calvente, PR; D'Almeida, V; Frussa, FR; Ribeiro, Rde A, 2002) |
| "Two primate models of Huntington's disease were analyzed: bilateral stereotactic intrastriatal injections of quinolinic acid (QA), and daily systemic intramuscular administration of 3-nitropropionic acid (3-NP) for up to 8 weeks in male Cebus apella monkeys." | 1.31 | Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. ( Emborg, ME; Kordower, JH; Palfi, S; Roitberg, BZ; Sramek, JG, 2002) |
| " Chronic administration of 3-nitropropionic acid (3-NP), a suicide inhibitor of succinate dehydrogenase, causes prolonged energy impairments and replicates most of the pathophysiological features of HD, including preferential striatal degeneration." | 1.31 | The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module. ( Besson, MJ; Brouillet, E; Caboche, J; Garcia, M; Pages, C; Vanhoutte, P, 2002) |
| "In adult-onset Huntington's disease (HD), striatal projection neurons are much more vulnerable than striatal interneurons, but even striatal projection neurons show differences in their vulnerability, with the striatal projection neurons projecting to the internal segment of the globus pallidus being the least vulnerable." | 1.31 | The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease. ( Reiner, A; Sun, Z; Xie, J, 2002) |
| "The gene defect in Huntington's disease (HD) may result in an impairment of energy metabolism." | 1.30 | Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. ( Beal, MF; Ferrante, RJ; Jenkins, BG; Kaddurah-Daouk, R; Matthews, RT; Rosen, BR; Yang, L, 1998) |
| "Huntington's disease is a progressive neurodegenerative disorder associated with severe degeneration of basal ganglia neurons, especially the intrinsic neurons of the striatum, and characterized by involuntary abnormal choreiform movements and progressive dementia." | 1.29 | Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease. ( Borlongan, CV; Cahill, DW; Freeman, TB; Koutouzis, TK; Sanberg, PR, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (6.58) | 18.2507 |
| 2000's | 114 (50.00) | 29.6817 |
| 2010's | 85 (37.28) | 24.3611 |
| 2020's | 14 (6.14) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 2 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Alshehri, S | 1 |
| Al-Abbasi, FA | 1 |
| Ghoneim, MM | 1 |
| Imam, SS | 1 |
| Afzal, M | 1 |
| Alharbi, KS | 1 |
| Nadeem, MS | 1 |
| Sayyed, N | 1 |
| Kazmi, I | 1 |
| Upadhayay, S | 1 |
| Yedke, NG | 1 |
| Rahi, V | 1 |
| Singh, S | 1 |
| Kumar, S | 1 |
| Arora, A | 1 |
| Chandolia, P | 1 |
| Kaur, P | 1 |
| Kumar, M | 2 |
| Koshal, P | 1 |
| Jamwal, S | 1 |
| Kumar, P | 7 |
| Sayed, NH | 1 |
| Fathy, N | 1 |
| Kortam, MA | 1 |
| Rabie, MA | 1 |
| Mohamed, AF | 1 |
| Kamel, AS | 1 |
| Moslemi, M | 1 |
| Khodagholi, F | 3 |
| Asadi, S | 1 |
| Rafiei, S | 1 |
| Motamedi, F | 1 |
| Glat, MJ | 2 |
| Stefanova, N | 9 |
| Wenning, GK | 11 |
| Offen, D | 2 |
| Wiprich, MT | 1 |
| Zanandrea, R | 1 |
| Altenhofen, S | 1 |
| Bonan, CD | 1 |
| Tai, CH | 1 |
| Pan, MK | 1 |
| Tseng, SH | 1 |
| Wang, TR | 1 |
| Kuo, CC | 1 |
| Eskandari, N | 2 |
| Boroujeni, ME | 2 |
| Abdollahifar, MA | 3 |
| Piryaei, A | 1 |
| Mirbehbahani, SH | 1 |
| Siroosi, S | 1 |
| Moghaddam, MH | 2 |
| Aliaghaei, A | 3 |
| Sadeghi, Y | 2 |
| Bayat, AH | 1 |
| Fotouhi, F | 1 |
| Forouzannia, A | 1 |
| Rafiei, R | 1 |
| Hatari, S | 1 |
| Seraj, A | 1 |
| Shahidi, AMEJ | 1 |
| Ghorbani, Z | 1 |
| Peyvandi, AA | 1 |
| Sharma, P | 1 |
| Bansal, N | 1 |
| Saad, MA | 1 |
| Ahmed, MAE | 1 |
| Elbadawy, NN | 1 |
| Abdelkader, NF | 1 |
| Fu, XX | 1 |
| Cai, HY | 1 |
| Jiang, H | 2 |
| Han, S | 1 |
| Silva-Palacios, A | 1 |
| Colín-González, AL | 1 |
| López-Cervantes, SP | 1 |
| Zazueta, C | 1 |
| Luna-López, A | 1 |
| Santamaría, A | 9 |
| Königsberg, M | 1 |
| Yanamandra, K | 1 |
| Patel, TK | 1 |
| Schindler, S | 1 |
| Ulrich, JD | 1 |
| Boxer, AL | 1 |
| Miller, BL | 1 |
| Kerwin, DR | 1 |
| Gallardo, G | 1 |
| Stewart, F | 1 |
| Finn, MB | 1 |
| Cairns, NJ | 1 |
| Verghese, PB | 1 |
| Fogelman, I | 1 |
| West, T | 1 |
| Braunstein, J | 1 |
| Robinson, G | 1 |
| Keyser, J | 1 |
| Roh, J | 1 |
| Knapik, SS | 1 |
| Hu, Y | 1 |
| Holtzman, DM | 1 |
| Wahdan, SA | 1 |
| Tadros, MG | 6 |
| Khalifa, AE | 6 |
| Kotlar, I | 1 |
| Colonnello, A | 1 |
| Aguilera-González, MF | 1 |
| Avila, DS | 1 |
| de Lima, ME | 1 |
| García-Contreras, R | 1 |
| Ortíz-Plata, A | 1 |
| Soares, FAA | 1 |
| Aschner, M | 1 |
| Nadal, X | 1 |
| Del Río, C | 1 |
| Casano, S | 1 |
| Palomares, B | 1 |
| Ferreiro-Vera, C | 1 |
| Navarrete, C | 2 |
| Sánchez-Carnerero, C | 1 |
| Cantarero, I | 2 |
| Bellido, ML | 2 |
| Meyer, S | 1 |
| Morello, G | 1 |
| Appendino, G | 1 |
| Muñoz, E | 2 |
| Gómez-Pineda, VG | 1 |
| Torres-Cruz, FM | 1 |
| Vivar-Cortés, CI | 1 |
| Hernández-Echeagaray, E | 1 |
| Ebrahimi, MJ | 1 |
| Meftahi, G | 1 |
| Ahmadi, H | 1 |
| Danyali, S | 1 |
| Daftari, M | 1 |
| Kim, HL | 1 |
| Chang, BJ | 1 |
| Nam, SM | 1 |
| Nahm, SS | 1 |
| Lee, JH | 3 |
| Ramachandran, S | 3 |
| Thangarajan, S | 3 |
| El-Abhar, H | 1 |
| Abd El Fattah, MA | 1 |
| Wadie, W | 1 |
| El-Tanbouly, DM | 1 |
| Kada, S | 1 |
| Hamaguchi, K | 1 |
| Ito, J | 1 |
| Omori, K | 1 |
| Nakagawa, T | 1 |
| Mealer, RG | 1 |
| Subramaniam, S | 1 |
| Snyder, SH | 1 |
| Shivasharan, BD | 1 |
| Nagakannan, P | 2 |
| Thippeswamy, BS | 2 |
| Veerapur, VP | 2 |
| Bansal, P | 1 |
| Unnikrishnan, MK | 1 |
| Sandhir, R | 3 |
| Yadav, A | 1 |
| Mehrotra, A | 3 |
| Sunkaria, A | 1 |
| Singh, A | 1 |
| Sharma, S | 1 |
| Pereira, GJ | 1 |
| Tressoldi, N | 1 |
| Hirata, H | 1 |
| Bincoletto, C | 1 |
| Smaili, SS | 2 |
| Chakraborty, J | 3 |
| Singh, R | 1 |
| Dutta, D | 1 |
| Naskar, A | 1 |
| Rajamma, U | 3 |
| Mohanakumar, KP | 5 |
| Liu, HG | 1 |
| Ma, Y | 1 |
| Meng, DW | 1 |
| Yang, AC | 1 |
| Zhang, JG | 2 |
| Nthenge-Ngumbau, DN | 1 |
| Gupta, S | 2 |
| Sharma, B | 2 |
| Souza, LC | 1 |
| Wilhelm, EA | 2 |
| Bortolatto, CF | 2 |
| Nogueira, CW | 2 |
| Boeira, SP | 1 |
| Jesse, CR | 2 |
| Fink, KD | 2 |
| Crane, AT | 1 |
| Lévêque, X | 2 |
| Dues, DJ | 1 |
| Huffman, LD | 1 |
| Moore, AC | 1 |
| Story, DT | 1 |
| Dejonge, RE | 1 |
| Antcliff, A | 1 |
| Starski, PA | 1 |
| Lu, M | 1 |
| Lescaudron, L | 2 |
| Rossignol, J | 2 |
| Dunbar, GL | 3 |
| Brouillet, E | 16 |
| Bracko, O | 1 |
| Di Pietro, V | 1 |
| Lazzarino, G | 1 |
| Amorini, AM | 1 |
| Tavazzi, B | 1 |
| Artmann, J | 1 |
| Wong, EC | 1 |
| Buxton, RB | 1 |
| Weller, M | 1 |
| Luft, AR | 1 |
| Wegener, S | 1 |
| Valdeolivas, S | 1 |
| Sagredo, O | 1 |
| Pandey, M | 3 |
| Navneet, AK | 2 |
| Appukuttan, TA | 1 |
| Varghese, M | 3 |
| Sreetama, SC | 1 |
| Török, R | 1 |
| Kónya, JA | 1 |
| Zádori, D | 1 |
| Veres, G | 1 |
| Szalárdy, L | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 5 |
| Gao, Y | 1 |
| Chu, SF | 1 |
| Li, JP | 1 |
| Zhang, Z | 1 |
| Yan, JQ | 1 |
| Wen, ZL | 1 |
| Xia, CY | 1 |
| Mou, Z | 1 |
| Wang, ZZ | 1 |
| He, WB | 1 |
| Guo, XF | 1 |
| Wei, GN | 1 |
| Chen, NH | 1 |
| Hanna, DM | 1 |
| Feng, Y | 1 |
| Wang, JQ | 1 |
| Kaindlstorfer, C | 1 |
| Sommer, P | 1 |
| Georgievska, B | 1 |
| Mather, RJ | 1 |
| Kugler, AR | 1 |
| Poewe, W | 7 |
| Sood, A | 1 |
| Qi, L | 1 |
| Sun, X | 1 |
| Li, FE | 1 |
| Zhu, BS | 1 |
| Braun, FK | 1 |
| Liu, ZQ | 1 |
| Tang, JL | 1 |
| Wu, C | 1 |
| Xu, F | 1 |
| Wang, HH | 1 |
| Velasquez, LA | 1 |
| Zhao, K | 1 |
| Lei, FR | 1 |
| Shen, YT | 1 |
| Zou, JX | 1 |
| Meng, HM | 1 |
| An, GL | 1 |
| Yang, L | 5 |
| Zhang, XD | 1 |
| Cho, KJ | 1 |
| Cheon, SY | 1 |
| Kim, GW | 1 |
| Menze, ET | 2 |
| Esmat, A | 1 |
| Abdel-Naim, AB | 2 |
| Dhadde, SB | 1 |
| Roopesh, M | 1 |
| Anand Kumar, SR | 1 |
| Badami, S | 1 |
| Ben-Zur, T | 1 |
| Barhum, Y | 1 |
| Skillings, EA | 1 |
| Morton, AJ | 3 |
| Kitao, K | 1 |
| Mizutari, K | 3 |
| Nakagawa, S | 3 |
| Matsunaga, T | 4 |
| Fukuda, S | 1 |
| Fujii, M | 4 |
| Orozco-Ibarra, M | 1 |
| García-Morales, J | 1 |
| Calvo-Silva, FJ | 1 |
| Fernández-Valverde, F | 1 |
| Serrano-García, N | 1 |
| Krishnamurthy, P | 1 |
| Wang, L | 1 |
| Wang, J | 1 |
| Zhou, SM | 1 |
| Guan, SY | 1 |
| Yang, LK | 1 |
| Shi, QX | 1 |
| Zhao, MG | 1 |
| Yang, Q | 1 |
| Malik, J | 1 |
| Karan, M | 1 |
| Dogra, R | 1 |
| He, Y | 1 |
| Akumuo, RC | 1 |
| Yang, Y | 1 |
| Hewett, SJ | 1 |
| Chen, SD | 1 |
| Wu, CL | 1 |
| Hwang, WC | 1 |
| Yang, DI | 1 |
| Li, XM | 1 |
| Zhu, BG | 1 |
| Ma, S | 1 |
| Zhou, W | 1 |
| Wei, Z | 1 |
| Zheng, YX | 1 |
| Zhao, XD | 1 |
| Zhu, RS | 1 |
| Pelegrí, C | 4 |
| Duran-Vilaregut, J | 4 |
| del Valle, J | 4 |
| Crespo-Biel, N | 3 |
| Ferrer, I | 1 |
| Pallàs, M | 9 |
| Camins, A | 9 |
| Vilaplana, J | 4 |
| Akopian, G | 1 |
| Crawford, C | 1 |
| Beal, MF | 13 |
| Cappelletti, M | 1 |
| Jakowec, MW | 1 |
| Petzinger, GM | 1 |
| Zheng, L | 1 |
| Gheorghe, SL | 1 |
| Reichel, CM | 1 |
| Chow, R | 1 |
| Walsh, JP | 1 |
| Gupta, R | 1 |
| Jha, A | 1 |
| Deshpande, SB | 2 |
| Acevedo-Torres, K | 1 |
| Berríos, L | 1 |
| Rosario, N | 1 |
| Dufault, V | 1 |
| Skatchkov, S | 1 |
| Eaton, MJ | 1 |
| Torres-Ramos, CA | 1 |
| Ayala-Torres, S | 1 |
| Park, JE | 5 |
| Lee, ST | 5 |
| Im, WS | 4 |
| Chu, K | 5 |
| Kim, M | 5 |
| Canudas, AM | 4 |
| Garcia, E | 1 |
| Limon, D | 1 |
| Perez-De La Cruz, V | 7 |
| Giordano, M | 1 |
| Diaz-Muñoz, M | 1 |
| Maldonado, PD | 2 |
| Herrera-Mundo, MN | 2 |
| Pedraza-Chaverri, J | 4 |
| Katakam, PV | 1 |
| Domoki, F | 1 |
| Snipes, JA | 1 |
| Busija, AR | 1 |
| Jarajapu, YP | 1 |
| Busija, DW | 1 |
| Elinos-Calderón, D | 3 |
| Robledo-Arratia, Y | 3 |
| Medina-Campos, ON | 1 |
| Ali, SF | 4 |
| O'Connor, T | 1 |
| Sadleir, KR | 1 |
| Maus, E | 1 |
| Velliquette, RA | 1 |
| Zhao, J | 1 |
| Cole, SL | 1 |
| Eimer, WA | 1 |
| Hitt, B | 1 |
| Bembinster, LA | 1 |
| Lammich, S | 1 |
| Lichtenthaler, SF | 1 |
| Hébert, SS | 1 |
| De Strooper, B | 1 |
| Haass, C | 2 |
| Bennett, DA | 1 |
| Vassar, R | 1 |
| Tsang, TM | 1 |
| Haselden, JN | 1 |
| Holmes, E | 1 |
| Kraft, JC | 1 |
| Osterhaus, GL | 1 |
| Ortiz, AN | 1 |
| Garris, PA | 1 |
| Johnson, MA | 2 |
| Ubhi, K | 2 |
| Lee, PH | 2 |
| Adame, A | 2 |
| Inglis, C | 2 |
| Mante, M | 2 |
| Rockenstein, E | 2 |
| Masliah, E | 2 |
| Borah, A | 1 |
| Barman, PK | 1 |
| Usha, R | 2 |
| Calingasan, NY | 3 |
| Wille, EJ | 1 |
| Cormier, K | 1 |
| Smith, K | 2 |
| Ferrante, RJ | 7 |
| Kumar, A | 6 |
| Choi, YS | 1 |
| Lee, B | 1 |
| Cho, HY | 1 |
| Reyes, IB | 1 |
| Pu, XA | 1 |
| Saido, TC | 1 |
| Hoyt, KR | 1 |
| Obrietan, K | 1 |
| Brunet, N | 1 |
| Tarabal, O | 1 |
| Esquerda, JE | 1 |
| Calderó, J | 1 |
| Lagoa, R | 1 |
| Lopez-Sanchez, C | 1 |
| Samhan-Arias, AK | 1 |
| Gañan, CM | 1 |
| Garcia-Martinez, V | 1 |
| Gutierrez-Merino, C | 1 |
| Gutiérrez-Cuesta, J | 1 |
| Melchiorri, D | 1 |
| Nicoletti, F | 1 |
| Cirillo, G | 1 |
| Maggio, N | 1 |
| Bianco, MR | 1 |
| Vollono, C | 1 |
| Sellitti, S | 1 |
| Papa, M | 1 |
| Cleren, C | 1 |
| Starkov, A | 2 |
| Jacquard, C | 3 |
| Chen, J | 1 |
| Galván-Arzate, S | 1 |
| Fujioka, M | 1 |
| Ogawa, K | 2 |
| Manich, G | 3 |
| Junyent, F | 2 |
| Lukács, A | 1 |
| Szabó, A | 1 |
| Papp, A | 1 |
| Vezér, T | 1 |
| Kalonia, H | 3 |
| Patrick, C | 1 |
| Kim, YH | 2 |
| Song, JJ | 1 |
| Kim, YC | 2 |
| Park, KT | 2 |
| Choi, JM | 1 |
| Oh, SH | 1 |
| Chang, SO | 1 |
| Túnez, I | 6 |
| Tasset, I | 2 |
| McConoughey, SJ | 1 |
| Basso, M | 1 |
| Niatsetskaya, ZV | 1 |
| Sleiman, SF | 1 |
| Smirnova, NA | 1 |
| Langley, BC | 1 |
| Mahishi, L | 1 |
| Cooper, AJ | 1 |
| Antonyak, MA | 1 |
| Cerione, RA | 1 |
| Li, B | 1 |
| Chaturvedi, RK | 1 |
| Coppola, G | 1 |
| Geschwind, DH | 1 |
| Ryu, H | 3 |
| Xia, L | 1 |
| Iismaa, SE | 1 |
| Pallos, J | 1 |
| Pasternack, R | 1 |
| Hils, M | 1 |
| Fan, J | 1 |
| Raymond, LA | 1 |
| Marsh, JL | 1 |
| Thompson, LM | 1 |
| Ratan, RR | 4 |
| Yoon, HJ | 1 |
| Im, JY | 1 |
| Park, KH | 1 |
| Jung, KH | 3 |
| Lee, SK | 1 |
| Roh, JK | 1 |
| Park, HJ | 1 |
| Bang, G | 1 |
| Lee, BR | 1 |
| Kim, HO | 1 |
| Boyer, C | 1 |
| Thinard, R | 1 |
| Blanchard, F | 1 |
| Mu, S | 1 |
| OuYang, L | 1 |
| Liu, B | 1 |
| Zhu, Y | 1 |
| Li, K | 1 |
| Zhan, M | 1 |
| Liu, Z | 1 |
| Jia, Y | 1 |
| Lei, W | 1 |
| Reiner, A | 2 |
| Chang, KL | 1 |
| New, LS | 1 |
| Mal, M | 1 |
| Goh, CW | 1 |
| Aw, CC | 1 |
| Browne, ER | 1 |
| Chan, EC | 1 |
| Mievis, S | 1 |
| Blum, D | 7 |
| Ledent, C | 2 |
| Köllensperger, M | 1 |
| Krismer, F | 1 |
| Pallua, A | 1 |
| Fantin, M | 1 |
| Morari, M | 1 |
| Tison, F | 8 |
| Fernagut, PO | 8 |
| Pontes, AJ | 1 |
| Hinojosa, AJ | 1 |
| de la Torre, R | 1 |
| Mahdy, HM | 1 |
| Mohamed, MR | 1 |
| Karim, AM | 1 |
| de Lemos, L | 1 |
| Verdaguer, E | 3 |
| Folch, J | 1 |
| Beas-Zárate, C | 1 |
| Auladell, C | 1 |
| Laço, MN | 1 |
| Oliveira, CR | 2 |
| Paulson, HL | 1 |
| Rego, AC | 2 |
| Mochel, F | 1 |
| Durant, B | 1 |
| Meng, X | 1 |
| O'Callaghan, J | 1 |
| Yu, H | 1 |
| Wheeler, VC | 1 |
| Humbert, S | 1 |
| Schiffmann, R | 1 |
| Durr, A | 1 |
| Colle, D | 1 |
| Hartwig, JM | 1 |
| Soares, FA | 1 |
| Farina, M | 1 |
| Dastidar, SG | 1 |
| Bardai, FH | 1 |
| Ma, C | 1 |
| Price, V | 1 |
| Rawat, V | 1 |
| Verma, P | 1 |
| Narayanan, V | 1 |
| D'Mello, SR | 2 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 2 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Chagas, PM | 1 |
| Abdel-Tawab, AM | 1 |
| Gopinath, K | 1 |
| Sudhandiran, G | 1 |
| Ventura, I | 1 |
| Russo, MT | 1 |
| De Nuccio, C | 1 |
| De Luca, G | 1 |
| Degan, P | 1 |
| Bernardo, A | 1 |
| Visentin, S | 1 |
| Minghetti, L | 2 |
| Bignami, M | 1 |
| Tian, C | 1 |
| Kim, SW | 1 |
| Kim, YJ | 1 |
| Lim, HJ | 1 |
| Choung, YH | 1 |
| Zou, J | 1 |
| Zhang, Y | 1 |
| Poe, D | 1 |
| Zhai, S | 1 |
| Yang, S | 1 |
| Pyykkö, I | 1 |
| Büchner, M | 1 |
| Huber, R | 1 |
| Sturchler-Pierrat, C | 1 |
| Staufenbiel, M | 1 |
| Riepe, MW | 2 |
| Kim, DY | 1 |
| Won, SJ | 1 |
| Gwag, BJ | 1 |
| Galas, MC | 5 |
| Gall, D | 4 |
| Cuvelier, L | 4 |
| Schiffmann, SN | 6 |
| Diguet, E | 4 |
| Biran, M | 1 |
| Canioni, P | 1 |
| Bioulac, B | 3 |
| d'Alcantara, P | 1 |
| Bantubungi, K | 4 |
| Ghorayeb, I | 2 |
| Lastres-Becker, I | 4 |
| de Miguel, R | 2 |
| De Petrocellis, L | 1 |
| Makriyannis, A | 1 |
| Di Marzo, V | 3 |
| Fernández-Ruiz, J | 6 |
| Li, H | 1 |
| Liu, C | 1 |
| Sun, S | 1 |
| Pubill, D | 2 |
| Sureda, FX | 2 |
| Camps, P | 1 |
| Muñoz-Torrero, D | 1 |
| Jiménez, A | 1 |
| Lee, J | 2 |
| Zaman, K | 1 |
| Kubilis, J | 1 |
| Ross, BD | 1 |
| Neve, R | 1 |
| Puschban, Z | 2 |
| Reindl, M | 2 |
| Jellinger, KA | 1 |
| Gibson, CL | 1 |
| Clowry, GJ | 1 |
| McBride, JL | 3 |
| During, MJ | 1 |
| Wuu, J | 1 |
| Chen, EY | 1 |
| Leurgans, SE | 1 |
| Kordower, JH | 4 |
| Bizat, N | 4 |
| Hermel, JM | 1 |
| Boyer, F | 3 |
| Créminon, C | 1 |
| Ouary, S | 5 |
| Escartin, C | 3 |
| Hantraye, P | 8 |
| Kajewski, S | 1 |
| Pintor, A | 2 |
| Muller, CE | 1 |
| Galluzzo, M | 1 |
| Rolland, AS | 1 |
| Popoli, P | 2 |
| Kubilus, JK | 1 |
| Beesen, A | 1 |
| Zucker, B | 1 |
| Kowall, NW | 1 |
| Luthi-Carter, R | 1 |
| Hersch, SM | 1 |
| Starkov, AA | 1 |
| Gardian, G | 1 |
| Browne, SE | 1 |
| Bubber, P | 1 |
| Gibson, GE | 1 |
| Patel, MS | 1 |
| Rosenstock, TR | 1 |
| Carvalho, AC | 1 |
| Jurkiewicz, A | 1 |
| Frussa-Filho, R | 1 |
| Normand, E | 1 |
| Centelles, L | 1 |
| Mulle, C | 1 |
| Lee, WT | 1 |
| Chang, C | 1 |
| Brownell, AL | 1 |
| Chen, YI | 1 |
| Yu, M | 1 |
| Wang, X | 1 |
| Dedeoglu, A | 4 |
| Cicchetti, F | 1 |
| Jenkins, BG | 2 |
| Wei, X | 1 |
| Du, Y | 1 |
| Rouland, R | 1 |
| Gross, C | 1 |
| Bezard, E | 2 |
| Chin, PC | 1 |
| Liu, L | 1 |
| Morrison, BE | 1 |
| Siddiq, A | 1 |
| Bottiglieri, T | 1 |
| Roberts, TJ | 2 |
| Montilla, P | 4 |
| Del Carmen Muñoz, M | 1 |
| Feijóo, M | 3 |
| Salcedo, M | 1 |
| Almeida, S | 1 |
| Domingues, A | 1 |
| Rodrigues, L | 1 |
| Zuchora, B | 1 |
| Wielosz, M | 1 |
| Urbańska, EM | 1 |
| Greco, A | 1 |
| Chtarto, A | 1 |
| Tai, K | 1 |
| Tenenbaum, L | 1 |
| Déglon, N | 2 |
| Brotchi, J | 1 |
| Levivier, M | 1 |
| Neumann, M | 1 |
| Kahle, PJ | 1 |
| Dalbem, A | 1 |
| Silveira, CV | 1 |
| Pedroso, MF | 1 |
| Breda, RV | 1 |
| Werne Baes, CV | 1 |
| Bartmann, AP | 1 |
| da Costa, JC | 1 |
| Kato, K | 1 |
| Shimazaki, K | 1 |
| Kamiya, T | 1 |
| Amemiya, S | 1 |
| Inaba, T | 1 |
| Oguro, K | 1 |
| Katayama, Y | 1 |
| de Lago, E | 2 |
| Urbani, P | 1 |
| Ramos, JA | 4 |
| Ortega-Gutiérrez, S | 1 |
| Cabranes, A | 1 |
| Pryce, G | 1 |
| Baker, D | 1 |
| López-Rodríguez, M | 1 |
| Tariq, M | 1 |
| Khan, HA | 1 |
| Elfaki, I | 1 |
| Al Deeb, S | 1 |
| Al Moutaery, K | 1 |
| von Arnim, CA | 1 |
| Verstege, E | 1 |
| Etrich, SM | 1 |
| Picconi, B | 2 |
| Passino, E | 1 |
| Sgobio, C | 1 |
| Bonsi, P | 1 |
| Barone, I | 1 |
| Ghiglieri, V | 1 |
| Pisani, A | 1 |
| Bernardi, G | 2 |
| Ammassari-Teule, M | 1 |
| Calabresi, P | 2 |
| Arafa, HM | 1 |
| Collado, JA | 2 |
| Medina, FJ | 3 |
| Peña, J | 3 |
| Del C Muñoz, M | 1 |
| Jimena, I | 3 |
| Franco, F | 2 |
| Rueda, I | 2 |
| Muntané, J | 2 |
| Zwingmann, C | 1 |
| Bilodeau, M | 1 |
| Price, J | 1 |
| Williams, SC | 1 |
| Modo, M | 1 |
| Drucker-Colín, R | 1 |
| Muñoz, Mdel C | 2 |
| Woodruff, TM | 1 |
| Crane, JW | 1 |
| Proctor, LM | 1 |
| Buller, KM | 1 |
| Shek, AB | 1 |
| de Vos, K | 1 |
| Pollitt, S | 1 |
| Williams, HM | 1 |
| Shiels, IA | 1 |
| Monk, PN | 1 |
| Taylor, SM | 1 |
| Hida, H | 1 |
| Takei-Io, N | 1 |
| Masuda, T | 1 |
| Baba, H | 1 |
| Nishino, H | 1 |
| Bjugstad, KB | 1 |
| Crnic, LS | 1 |
| Goodman, SI | 1 |
| Freed, CR | 1 |
| Kang, L | 3 |
| Ko, SY | 1 |
| Binienda, ZK | 1 |
| Virmani, A | 1 |
| Amato, A | 1 |
| Salem, N | 1 |
| Przybyla, BD | 1 |
| Rossi, S | 1 |
| Prosperetti, C | 1 |
| De Chiara, V | 1 |
| Mataluni, G | 1 |
| Centonze, D | 1 |
| Ayala, A | 1 |
| Venero, JL | 1 |
| Cano, J | 1 |
| Machado, A | 1 |
| Ramaswamy, S | 2 |
| Herzog, CD | 1 |
| Brandon, E | 1 |
| Gasmi, M | 1 |
| Bartus, RT | 1 |
| Kamiya, K | 2 |
| Fujinami, Y | 2 |
| Hoya, N | 1 |
| Okamoto, Y | 1 |
| Kouike, H | 1 |
| Komatsuzaki, R | 1 |
| Kusano, R | 1 |
| Satoh, H | 1 |
| Villanueva, M | 1 |
| Haynes, CL | 1 |
| Seipel, AT | 1 |
| Buhler, LA | 1 |
| Wightman, RM | 1 |
| Bemelmans, AP | 1 |
| Sindhu, KM | 1 |
| Sreetama, S | 1 |
| Hong, NH | 1 |
| Han, Z | 1 |
| Kim, MW | 2 |
| Kim, DH | 1 |
| Kim, S | 1 |
| Jung, SH | 1 |
| Silva-Adaya, D | 1 |
| Mendoza-Macedo, K | 1 |
| Villeda-Hernández, J | 1 |
| Binienda, Z | 1 |
| Dhir, A | 1 |
| Akula, KK | 1 |
| Kulkarni, SK | 1 |
| Borlongan, CV | 4 |
| Koutouzis, TK | 3 |
| Randall, TS | 2 |
| Freeman, TB | 2 |
| Cahill, DW | 3 |
| Sanberg, PR | 4 |
| Galpern, WR | 1 |
| Matthews, RT | 3 |
| Isacson, O | 1 |
| Miller, PJ | 1 |
| Zaborszky, L | 1 |
| Kodsi, MH | 1 |
| Swerdlow, NR | 1 |
| Schulz, JB | 1 |
| Klockgether, T | 1 |
| Dichgans, J | 1 |
| Rosen, BR | 1 |
| Kaddurah-Daouk, R | 1 |
| Reynolds, NC | 1 |
| Lin, W | 1 |
| Meyer Cameron, C | 1 |
| Roerig, DL | 1 |
| Reynolds, DS | 1 |
| Carter, RJ | 1 |
| Shear, DA | 1 |
| Dong, J | 1 |
| Gundy, CD | 1 |
| Haik-Creguer, KL | 1 |
| Andreassen, OA | 3 |
| Mueller, G | 1 |
| Lancelot, E | 1 |
| Bogdanov, M | 1 |
| Andersen, JK | 1 |
| Jiang, D | 1 |
| Altairac, S | 1 |
| Ménétrat, H | 1 |
| Mittoux, V | 3 |
| Condé, F | 3 |
| Aubert, I | 1 |
| Joseph, JM | 1 |
| Palfi, S | 2 |
| Dautry, C | 1 |
| Poyot, T | 2 |
| Bloch, J | 1 |
| Nimchinsky, EA | 1 |
| Hof, PR | 1 |
| Peschanski, M | 2 |
| Aebischer, P | 1 |
| Storgaard, J | 1 |
| Kornblit, BT | 1 |
| Zimmer, J | 1 |
| Gramsbergen, JB | 1 |
| Hughes, DB | 1 |
| Ona, VO | 1 |
| Friedlander, RM | 1 |
| Hickey, MA | 1 |
| Canals, JM | 1 |
| Checa, N | 1 |
| Marco, S | 1 |
| Akerud, P | 1 |
| Michels, A | 1 |
| Pérez-Navarro, E | 1 |
| Tolosa, E | 1 |
| Arenas, E | 1 |
| Alberch, J | 1 |
| Escubedo, E | 1 |
| Camarasa, J | 1 |
| Albers, DW | 1 |
| Carlson, EJ | 1 |
| Epstein, CJ | 1 |
| Yu, Z | 1 |
| Zhou, D | 1 |
| Cheng, G | 1 |
| Mattson, MP | 1 |
| Waldner, R | 1 |
| Scherfler, C | 1 |
| Seppi, K | 1 |
| Jellinger, K | 1 |
| Vis, JC | 1 |
| Verbeek, MM | 1 |
| de Waal, RM | 1 |
| ten Donkelaar, HJ | 1 |
| Kremer, B | 1 |
| Demougeot, C | 1 |
| Garnier, P | 1 |
| Mossiat, C | 1 |
| Bertrand, N | 1 |
| Giroud, M | 1 |
| Beley, A | 1 |
| Marie, C | 1 |
| Fezza, F | 1 |
| Cebeira, M | 1 |
| Bisogno, T | 1 |
| Milone, A | 1 |
| Teunissen, CE | 1 |
| Steinbusch, HW | 1 |
| Angevaren, M | 1 |
| Appels, M | 1 |
| de Bruijn, C | 1 |
| Prickaerts, J | 1 |
| de Vente, J | 1 |
| Keene, CD | 1 |
| Rodrigues, CM | 1 |
| Eich, T | 1 |
| Linehan-Stieers, C | 1 |
| Abt, A | 1 |
| Kren, BT | 1 |
| Steer, CJ | 1 |
| Low, WC | 1 |
| El Massioui, N | 1 |
| Chéruel, F | 1 |
| Calvente, PR | 1 |
| Araujo, CC | 1 |
| Bergamo, M | 1 |
| Abilio, VC | 1 |
| D'Almeida, V | 1 |
| Ribeiro, Rde A | 1 |
| Frussa, FR | 1 |
| Hansen, HH | 1 |
| Berrendero, F | 1 |
| Pérez-Rosado, A | 1 |
| Manzanares, J | 1 |
| Roitberg, BZ | 1 |
| Emborg, ME | 1 |
| Sramek, JG | 1 |
| Garcia, M | 1 |
| Vanhoutte, P | 1 |
| Pages, C | 1 |
| Besson, MJ | 1 |
| Caboche, J | 1 |
| Monville, C | 1 |
| Lisovoski, F | 1 |
| Robichon, R | 1 |
| Sun, Z | 1 |
| Xie, J | 1 |
| Arias, C | 1 |
| Montiel, T | 1 |
| Quiroz-Báez, R | 1 |
| Massieu, L | 1 |
| Liu, X | 1 |
| Luo, X | 1 |
| Hu, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ursodiol in Huntington's Disease[NCT00514774] | Phase 1 | 21 participants (Anticipated) | Interventional | 2007-08-31 | Active, not recruiting | ||
| A Randomized, Double-blind Multicenter Pilot Study vs. Placebo for the Evaluation of Efficacy and Tolerability of Tauroursodeoxycholic Acid Administered by Oral Route as Add on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis[NCT00877604] | Phase 2 | 34 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Responder patients were defined as those subjects showing an improvement of at least 15% in the ALSFRS-R slope during the treatment period as compared to the lead-in period. (NCT00877604)
Timeframe: 1 year
| Intervention | participants (Number) |
|---|---|
| TUDCA | 13 |
| Placebo | 6 |
11 reviews available for 3-nitropropionic acid and Disease Models, Animal
| Article | Year |
|---|---|
An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development.
Topics: Animals; Disease Models, Animal; Drug Discovery; Huntington Disease; Neurotoxins; Nitro Compounds; P | 2023 |
More Insight into BDNF against Neurodegeneration: Anti-Apoptosis, Anti-Oxidation, and Suppression of Autophagy.
Topics: Animals; Apoptosis; Autophagy; Brain-Derived Neurotrophic Factor; Cells, Cultured; Disease Models, A | 2017 |
3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Nitro Compounds; Propionates | 2010 |
Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease.
Topics: Animals; Brain; Convulsants; Disease Models, Animal; Humans; Huntington Disease; Magnetic Resonance | 2004 |
Mitochondrial toxins and neurodegenerative diseases.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Mitochondria; MPTP Poisoning; Neurodege | 2007 |
Integrative hypothesis for Huntington's disease: a brief review of experimental evidence.
Topics: Animals; Calcium; Cell Death; Disease Models, Animal; Energy Metabolism; Excitatory Amino Acids; Hum | 2007 |
Animal models of Huntington's disease.
Topics: Animals; Disease Models, Animal; Disease Progression; Genetic Vectors; Huntington Disease; Lentiviru | 2007 |
Neurochemistry and toxin models in Huntington's disease.
Topics: Animals; Coenzymes; Disease Models, Animal; Energy Metabolism; Humans; Huntington Disease; Mitochond | 1994 |
Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antihypertensive Agents; Disease Models, Anim | 1995 |
3-Nitropropionic acid animal model and Huntington's disease.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Huntington Disease; Nitro Compounds; Propi | 1997 |
The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agents; Hydr | 1997 |
217 other studies available for 3-nitropropionic acid and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Anti-Huntington's Effect of Butin in 3-Nitropropionic Acid-Treated Rats: Possible Mechanism of Action.
Topics: Animals; Behavior, Animal; Benzopyrans; Disease Models, Animal; Huntington Disease; Mice; Motor Acti | 2022 |
Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
Topics: Animals; Behavior, Animal; Brain-Derived Neurotrophic Factor; Corpus Striatum; Dipeptidyl-Peptidase | 2020 |
Oxytocin protects against 3-NP induced learning and memory impairment in rats: Sex differences in behavioral and molecular responses to the context of prenatal stress.
Topics: Animals; Behavior, Animal; Brain; Cognitive Dysfunction; Conditioning, Operant; Disease Models, Anim | 2020 |
Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy.
Topics: Animals; Behavior, Animal; Convulsants; Corpus Striatum; Disease Models, Animal; Excitatory Amino Ac | 2020 |
Influence of 3-nitropropionic acid on physiological and behavioral responses in zebrafish larvae and adults.
Topics: Aggression; Animals; Antihypertensive Agents; Behavior, Animal; Disease Models, Animal; Heart Rate; | 2020 |
Hyperpolarization of the subthalamic nucleus alleviates hyperkinetic movement disorders.
Topics: Animals; Cell Polarity; Deep Brain Stimulation; Disease Models, Animal; Humans; Hyperkinesis; Levodo | 2020 |
Transplantation of human dental pulp stem cells compensates for striatal atrophy and modulates neuro-inflammation in 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Atrophy; Dental Pulp; Disease Models, Animal; Humans; Huntington Disease; Inflammation; Nit | 2021 |
Elderberry diet ameliorates motor function and prevents oxidative stress-induced cell death in rat models of Huntington disease.
Topics: Animals; Cell Death; Disease Models, Animal; Electric Stimulation; Electromyography; Huntington Dise | 2021 |
Ellagic acid prevents 3-nitropropionic acid induced symptoms of Huntington's disease.
Topics: Animals; Catalase; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; El | 2021 |
Nano-ivabradine averts behavioral anomalies in Huntington's disease rat model via modulating Rhes/m-tor pathway.
Topics: Animals; Autophagy; Cardiovascular Agents; Corpus Striatum; Disease Models, Animal; Huntington Disea | 2021 |
Combined treatment with C16 peptide and angiopoietin-1 confers neuroprotection and reduces inflammation in 3-nitropropionic acid-induced dystonia mice.
Topics: Angiopoietin-1; Animals; Anti-Inflammatory Agents; Brain; Capillary Permeability; Central Nervous Sy | 2021 |
Tert-buthylhydroquinone pre-conditioning exerts dual effects in old female rats exposed to 3-nitropropionic acid.
Topics: Animals; Cell Nucleus; Disease Models, Animal; Female; Huntington Disease; Hydroquinones; Neuroprote | 2017 |
Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.
Topics: Animals; Antibodies; Brain; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; | 2017 |
Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats.
Topics: Animals; Antioxidants; Apoptosis; Catalase; Disease Models, Animal; Dose-Response Relationship, Drug | 2017 |
Comparison of the Toxic Effects of Quinolinic Acid and 3-Nitropropionic Acid in C. elegans: Involvement of the SKN-1 Pathway.
Topics: Animals; Antihypertensive Agents; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Corpus St | 2018 |
Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.
Topics: Animals; Cannabis; Cell Line, Tumor; Disease Models, Animal; Dronabinol; Humans; Huntingtin Protein; | 2017 |
Neurotrophin-3 restores synaptic plasticity in the striatum of a mouse model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Male; Membrane Glycoproteins; | 2018 |
Human Umbilical Cord Matrix Stem Cells Reverse Oxidative Stress-Induced Cell Death and Ameliorate Motor Function and Striatal Atrophy in Rat Model of Huntington Disease.
Topics: Animals; Antigens, CD; Cell Death; Cell Differentiation; Cell Line; Convulsants; Cord Blood Stem Cel | 2018 |
Increased osteopontin expression and mitochondrial swelling in 3-nitropropionic acid-injured rat brains.
Topics: Animals; Brain; Disease Models, Animal; Male; Mitochondrial Swelling; Nitro Compounds; Osteopontin; | 2017 |
Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington's disease.
Topics: Animals; Benzoquinones; Disease Models, Animal; Drug Delivery Systems; Encephalitis; Huntington Dise | 2018 |
Cilostazol disrupts TLR-4, Akt/GSK-3β/CREB, and IL-6/JAK-2/STAT-3/SOCS-3 crosstalk in a rat model of Huntington's disease.
Topics: Animals; Apoptosis; Cilostazol; Corpus Striatum; CREB-Binding Protein; Cyclic AMP Response Element-B | 2018 |
Bone Marrow Stromal Cells Accelerate Hearing Recovery via Regeneration or Maintenance of Cochlear Fibrocytes in Mouse Spiral Ligaments.
Topics: Animals; Cochlea; Disease Models, Animal; Evoked Potentials, Auditory, Brain Stem; Female; Hearing L | 2020 |
Rhes deletion is neuroprotective in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Exploratory Behavior; GTP-Binding Proteins; Huntington Disease; Mic | 2013 |
Protective effect of Calendula officinalis Linn. flowers against 3-nitropropionic acid induced experimental Huntington's disease in rats.
Topics: Analysis of Variance; Animals; Body Weight; Calendula; Chromatography, High Pressure Liquid; Disease | 2013 |
Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease.
Topics: Animals; Ataxia; Corpus Striatum; Curcumin; Disease Models, Animal; Drug Evaluation, Preclinical; Fe | 2014 |
Autophagy as a neuroprotective mechanism against 3-nitropropionic acid-induced murine astrocyte cell death.
Topics: Adenine; Animals; Apoptosis; Apoptosis Regulatory Proteins; Astrocytes; Autophagy; bcl-2-Associated | 2013 |
Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's Disease.
Topics: Animals; Antioxidants; Astrocytes; Cell Proliferation; Cerebral Cortex; Corpus Striatum; Disease Mod | 2014 |
A rat model of hemidystonia induced by 3-nitropropionic acid.
Topics: Animals; Disease Models, Animal; Dystonic Disorders; Electromyography; Histological Techniques; Magn | 2013 |
Mitochondrial cofactors in experimental Huntington's disease: behavioral, biochemical and histological evaluation.
Topics: Acetylcarnitine; Animals; Antioxidants; Behavior, Animal; Brain; Chromatography, Thin Layer; Disease | 2014 |
Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease.
Topics: Animals; Convulsants; Dendritic Spines; Disease Models, Animal; Dose-Response Relationship, Drug; Dr | 2014 |
Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Brain; Disease Models, Animal; Ditiocarb; Huntington | 2014 |
Involvement of mGlu5 receptor in 3-nitropropionic acid-induced oxidative stress in rat striatum.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Beha | 2014 |
Intrastriatal transplantation of adenovirus-generated induced pluripotent stem cells for treating neuropathological and functional deficits in a rodent model of Huntington's disease.
Topics: Adenoviridae; Animals; Behavior, Animal; Convulsants; Corpus Striatum; Disease Models, Animal; Femal | 2014 |
Pharmacological benefits of agomelatine and vanillin in experimental model of Huntington's disease.
Topics: Acetamides; Animals; Benzaldehydes; Disease Models, Animal; Female; Huntington Disease; Male; Maze L | 2014 |
The 3-NP Model of Striatal Neurodegeneration.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Male; Neurodegenerative Diseas | 2014 |
3-Nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood flow.
Topics: Animals; Antihypertensive Agents; Brain Ischemia; Cerebral Angiography; Cerebrovascular Circulation; | 2014 |
Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.
Topics: Animals; Brain; Cannabinoids; Disease Models, Animal; Huntington Disease; Male; Mice; Mice, Inbred C | 2015 |
Profilin-2 increased expression and its altered interaction with β-actin in the striatum of 3-nitropropionic acid-induced Huntington's disease in rats.
Topics: Actins; Animals; Cell Culture Techniques; Cerebral Cortex; Convulsants; Dendritic Spines; Disease Mo | 2014 |
mRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease.
Topics: Animals; Disease Models, Animal; Female; Gene Expression Regulation; Huntington Disease; Male; Mice, | 2015 |
Protopanaxtriol protects against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington's disease.
Topics: Animals; Antioxidants; Basal Ganglia; Behavior, Animal; Disease Models, Animal; Dose-Response Relati | 2015 |
ADIOL protects against 3-NP-induced neurotoxicity in rats: Possible impact of its anti-oxidant, anti-inflammatory and anti-apoptotic actions.
Topics: Analysis of Variance; Androstenedione; Animals; Antioxidants; Apoptosis; Body Weight; Caspase 3; Cat | 2015 |
microRNA-33A expression is reduced in cerebral cortex in a rat model of ischemic tolerance.
Topics: Animals; Atropine; Cerebral Cortex; Disease Models, Animal; Gene Expression Regulation; Infarction, | 2015 |
Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Enzyme Inhibitors; Humans; Male; Mice, Tran | 2015 |
Mitochondrial modulators improve lipid composition and attenuate memory deficits in experimental model of Huntington's disease.
Topics: Acetylcarnitine; Animals; Behavior, Animal; Brain; Cholesterol; Chromatography, Thin Layer; Cognitio | 2015 |
HMGB1 Promotes Mitochondrial Dysfunction-Triggered Striatal Neurodegeneration via Autophagy and Apoptosis Activation.
Topics: Animals; Apoptosis; Autophagy; Caspase 3; Cell Proliferation; Cells, Cultured; Corpus Striatum; Dise | 2015 |
Apoptosis signal-regulating kinase 1 mediates striatal degeneration via the regulation of C1q.
Topics: Animals; Astrocytes; Cell Death; Complement C1q; Corpus Striatum; Dendrites; Disease Models, Animal; | 2016 |
Genistein improves sensorimotor gating: Mechanisms related to its neuroprotective effects on the striatum.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apoptosis; Corpus Striatum; Dinoprostone; Disease Mod | 2016 |
Effect of embelin against 3-nitropropionic acid-induced Huntington's disease in rats.
Topics: Animals; Behavior, Animal; Benzoquinones; Body Weight; Brain; Catalase; Disease Models, Animal; Dose | 2016 |
Neuroprotective Effect of a DJ-1 Based Peptide in a Toxin Induced Mouse Model of Multiple System Atrophy.
Topics: Animals; Disease Models, Animal; Male; Mice; Microtubule-Associated Proteins; Multiple System Atroph | 2016 |
Delayed Onset and Reduced Cognitive Deficits through Pre-Conditioning with 3-Nitropropionic Acid is Dependent on Sex and CAG Repeat Length in the R6/2 Mouse Model of Huntington's Disease.
Topics: Aging; Animals; Cognitive Dysfunction; Disease Models, Animal; Female; Humans; Huntington Disease; M | 2016 |
A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington's disease-like symptoms in wistar rats.
Topics: Animals; Benzoquinones; Corpus Striatum; Disease Models, Animal; Drug Carriers; Huntington Disease; | 2016 |
Recovery of endocochlear potential after severe damage to lateral wall fibrocytes following acute cochlear energy failure.
Topics: Animals; Cochlear Diseases; Connexin 26; Disease Models, Animal; Electroencephalography; Evoked Pote | 2016 |
Striatal mitochondria response to 3-nitropropionic acid and fish oil treatment.
Topics: Animals; Antioxidants; Corpus Striatum; Cytochrome-c Peroxidase; Disease Models, Animal; Dose-Respon | 2018 |
Chrysin exerts neuroprotective effects against 3-Nitropropionic acid induced behavioral despair-Mitochondrial dysfunction and striatal apoptosis via upregulating Bcl-2 gene and downregulating Bax-Bad genes in male wistar rats.
Topics: Animals; Apoptosis; Basal Ganglia; bcl-2-Associated X Protein; bcl-Associated Death Protein; Behavio | 2016 |
Effect of Praeruptorin C on 3-nitropropionic acid induced Huntington's disease-like symptoms in mice.
Topics: Animals; Coumarins; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; | 2017 |
Ameliorating effect of Celastrus paniculatus standardized extract and its fractions on 3-nitropropionic acid induced neuronal damage in rats: possible antioxidant mechanism.
Topics: Animals; Antioxidants; Behavior, Animal; Biomarkers; Brain; Celastrus; Chromatography, Thin Layer; C | 2017 |
Mice deficient in L-12/15 lipoxygenase show increased vulnerability to 3-nitropropionic acid neurotoxicity.
Topics: Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Corpus Striatum; Disease Models | 2017 |
Depressive-like behavior in mice recently recovered from motor disorders after 3-nitropropionic acid intoxication.
Topics: Animals; Convulsants; Corpus Striatum; Depression; Disease Models, Animal; Mice; Motor Activity; Nit | 2008 |
Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid.
Topics: Animals; Apoptosis; Cell Cycle Proteins; Convulsants; Corpus Striatum; Cyclin D1; Disease Models, An | 2008 |
Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia.
Topics: Animals; Cerebral Cortex; Convulsants; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine A | 2008 |
3-Nitropropionic acid-induced depression of spinal reflexes does not involve 5-hydroxytryptaminergic system in contrast to ischemia-induced depression in neonatal rat spinal cord in vitro.
Topics: Animals; Animals, Newborn; Brain Diseases, Metabolic; Disease Models, Animal; Electric Stimulation; | 2008 |
Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease.
Topics: Animals; Cell Nucleus; Cerebral Cortex; Disease Models, Animal; DNA Damage; DNA, Mitochondrial; Guan | 2009 |
Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, | 2008 |
Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro.
Topics: Animals; Calcium; Calpain; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinase 5; Disease Models | 2009 |
Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Basal Ganglia; Behavior, Animal | 2008 |
Impaired mitochondria-dependent vasodilation in cerebral arteries of Zucker obese rats with insulin resistance.
Topics: Animals; Cerebral Arteries; Cyclooxygenase Inhibitors; Diazoxide; Disease Models, Animal; Dose-Respo | 2009 |
Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lipid Peroxidation; Male; Meta | 2009 |
Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis.
Topics: Age Factors; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precu | 2008 |
Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Behavior, Animal; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Choline; Corpus Striatum; | 2009 |
In vivo dopamine release and uptake impairments in rats treated with 3-nitropropionic acid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Central Nervous System Agents; Chroma | 2009 |
Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Brain; Convulsants; Disease Models, Animal; Mice; Mice, Transgenic; Mitoch | 2009 |
Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats.
Topics: Animals; Convulsants; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Respo | 2009 |
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis | 2009 |
Early nerve ending rescue from oxidative damage and energy failure by L: -carnitine as post-treatment in two neurotoxic models in rat: recovery of antioxidant and reductive capacities.
Topics: Animals; Antioxidants; Brain; Carnitine; Disease Models, Animal; Dose-Response Relationship, Drug; E | 2009 |
Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Behavior, Animal; Brain; Catalase; Disease Models, An | 2009 |
CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease.
Topics: Animals; Cells, Cultured; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Mode | 2009 |
Excitotoxic motoneuron degeneration induced by glutamate receptor agonists and mitochondrial toxins in organotypic cultures of chick embryo spinal cord.
Topics: Animals; Calcium Signaling; Chick Embryo; Disease Models, Animal; Dose-Response Relationship, Drug; | 2009 |
Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid.
Topics: Animals; Calpain; Caspases; Convulsants; Corpus Striatum; Creatine Kinase; Disease Models, Animal; H | 2009 |
Regulation of GSK-3beta by calpain in the 3-nitropropionic acid model.
Topics: Amino Acid Chloromethyl Ketones; Aminophenols; Animals; Calpain; Caspases; Cell Survival; Cells, Cul | 2010 |
Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington's like symptoms in rats: possible role of nitric oxide.
Topics: Analysis of Variance; Animals; Antioxidants; Body Weight; Catalase; Corpus Striatum; Disease Models, | 2010 |
Protective effects of epigallocatechin gallate following 3-nitropropionic acid-induced brain damage: possible nitric oxide mechanisms.
Topics: Animals; Antioxidants; Behavior, Animal; Catechin; Disease Models, Animal; Dose-Response Relationshi | 2009 |
Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats.
Topics: Animals; Astrocytes; Basal Ganglia; Basal Ganglia Diseases; Behavior, Animal; Disability Evaluation; | 2010 |
Promethazine protects against 3-nitropropionic acid-induced neurotoxicity.
Topics: Amyotrophic Lateral Sclerosis; Animals; Brain Ischemia; Disease Models, Animal; Huntington Disease; | 2010 |
Antioxidant strategy to rescue synaptosomes from oxidative damage and energy failure in neurotoxic models in rats: protective role of S-allylcysteine.
Topics: Animals; Antioxidants; Brain; Corpus Striatum; Cysteine; Disease Models, Animal; Dyskinesia, Drug-In | 2010 |
Balance dysfunction resulting from acute inner ear energy failure is caused primarily by vestibular hair cell damage.
Topics: Animals; Caloric Tests; Cochlea; Disease Models, Animal; Dose-Response Relationship, Drug; Hair Cell | 2010 |
Systemic administration of 3-nitropropionic acid points out a different role for active caspase-3 in neurons and astrocytes.
Topics: Animals; Apoptosis; Astrocytes; Caspase 3; Convulsants; Corpus Striatum; Disease Models, Animal; Enz | 2010 |
Altered open field behavior in rats induced by acute administration of 3-nitropropionic acid: possible glutamatergic and dopaminergic involvement.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine D2 | 2009 |
Protective effect of sesamol against 3-nitropropionic acid-induced cognitive dysfunction and altered glutathione redox balance in rats.
Topics: Animals; Behavior, Animal; Benzodioxoles; Cognition Disorders; Disease Models, Animal; Escape Reacti | 2010 |
Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Mice; Mice, Knockout; Mice, Transgenic; Mul | 2010 |
Geranylgeranylacetone ameliorates acute cochlear damage caused by 3-nitropropionic acid.
Topics: Acoustic Stimulation; Animals; Auditory Threshold; Cochlear Diseases; Disease Models, Animal; Diterp | 2010 |
Nitric oxide mechanism in the protective effect of antidepressants against 3-nitropropionic acid-induced cognitive deficit, glutathione and mitochondrial alterations in animal model of Huntington's disease.
Topics: Animals; Antidepressive Agents; Cognition Disorders; Convulsants; Disease Models, Animal; Dose-Respo | 2010 |
Possible nitric oxide modulation in protective effect of FK-506 against 3-nitropropionic acid-induced behavioral, oxidative, neurochemical, and mitochondrial alterations in rat brain.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Brain Chemistry; Disease Models, Animal; Huntington D | 2010 |
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.
Topics: Amino Acid Sequence; Animals; Cell Line, Tumor; Cytochromes c; Disease Models, Animal; Drosophila; E | 2010 |
Altered microRNA regulation in Huntington's disease models.
Topics: Animals; Chromosomes, Artificial, Yeast; Disease Models, Animal; Down-Regulation; Huntingtin Protein | 2011 |
Neuroprotective effect of human mesenchymal stem cells in an animal model of double toxin-induced multiple system atrophy parkinsonism.
Topics: Animals; bcl-2-Associated X Protein; Corpus Striatum; Cytochromes c; Disease Models, Animal; Humans; | 2011 |
Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes.
Topics: Animals; Behavior, Animal; Brain; Cell Differentiation; Cells, Cultured; Convulsants; Disease Models | 2011 |
Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Blood-Brain Barrier; Corpus Striatum; Disease Models, Animal; Huntington Disease; Immunohis | 2011 |
Preferential interneuron survival in the transition zone of 3-NP-induced striatal injury in rats.
Topics: Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; Huntington Disease; Interneurons; M | 2011 |
Metabolic profiling of 3-nitropropionic acid early-stage Huntington's disease rat model using gas chromatography time-of-flight mass spectrometry.
Topics: Animals; Brain; Disease Models, Animal; Electron Transport Complex II; Galantamine; Gas Chromatograp | 2011 |
Worsening of Huntington disease phenotype in CB1 receptor knockout mice.
Topics: Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Disease Progression; Female; | 2011 |
Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Cell Death; Convulsants; Corpus Striatum; Disease Models, Animal; Dopamine | 2011 |
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Antagonists; Huntington Dise | 2011 |
Olive oil reduces oxidative damage in a 3-nitropropionic acid-induced Huntington's disease-like rat model.
Topics: Administration, Oral; Animals; Antioxidants; Corpus Striatum; Disease Models, Animal; Glutathione; H | 2011 |
The effect of Ginkgo biloba extract on 3-nitropropionic acid-induced neurotoxicity in rats.
Topics: Animals; Antioxidants; Disease Models, Animal; Down-Regulation; Ginkgo biloba; Huntington Disease; M | 2011 |
Lack of Jun-N-terminal kinase 3 (JNK3) does not protect against neurodegeneration induced by 3-nitropropionic acid.
Topics: Animals; Blotting, Western; Convulsants; Corpus Striatum; Disease Models, Animal; Enzyme Activation; | 2012 |
Compromised mitochondrial complex II in models of Machado-Joseph disease.
Topics: Animals; Ataxin-3; Cell Death; Cell Line; Cell Line, Transformed; Cells, Cultured; Cerebellum; Disea | 2012 |
Early alterations of brain cellular energy homeostasis in Huntington disease models.
Topics: Adenosine Triphosphate; Animals; Brain Chemistry; Convulsants; Disease Models, Animal; Energy Metabo | 2012 |
Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
Topics: Animals; Antioxidants; Convulsants; Corpus Striatum; Disease Models, Animal; Huntington Disease; Lip | 2012 |
Isoform-specific toxicity of Mecp2 in postmitotic neurons: suppression of neurotoxicity by FoxG1.
Topics: Animals; Animals, Newborn; Apoptosis; Cells, Cultured; Cerebellum; Disease Models, Animal; Female; F | 2012 |
Expression pattern of ataxia telangiectasia mutated (ATM), p53, Akt, and glycogen synthase kinase-3β in the striatum of rats treated with 3-nitropropionic acid.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Convulsants; Corpus Striatum; | 2012 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Organoselenium bis selenide attenuates 3-nitropropionic acid-induced neurotoxicity in rats.
Topics: Animals; Ataxia; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Eva | 2013 |
Potential neuroprotective effects of hesperidin on 3-nitropropionic acid-induced neurotoxicity in rats.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Brain; Catalase; Convulsants; Disease Models, A | 2012 |
Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway.
Topics: Administration, Oral; Analysis of Variance; Animals; Convulsants; Corpus Striatum; Cyclooxygenase 2; | 2012 |
hMTH1 expression protects mitochondria from Huntington's disease-like impairment.
Topics: Animals; Brain; Cell Death; Cell Line; Cells, Cultured; Disease Models, Animal; DNA Repair Enzymes; | 2013 |
Korean red ginseng ameliorates acute 3-nitropropionic acid-induced cochlear damage in mice.
Topics: Animals; Auditory Threshold; Cochlea; Cochlear Diseases; Cytoprotection; Disease Models, Animal; Dos | 2013 |
Mitochondria toxin-induced acute cochlear cell death indicates cellular activity-correlated energy consumption.
Topics: Animals; Auditory Threshold; Cell Death; Cochlea; Disease Models, Animal; DNA Fragmentation; Evoked | 2013 |
Impaired hypoxic tolerance and altered protein binding of NADH in presymptomatic APP23 transgenic mice.
Topics: Action Potentials; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Anima | 2002 |
Analysis of mitochondrial free radical generation in animal models of neuronal disease.
Topics: Adenosine Triphosphate; Animals; Brain Ischemia; Disease Models, Animal; Fluorescent Dyes; Free Radi | 2002 |
Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease.
Topics: Animals; Brain Chemistry; Cerebral Cortex; Chronic Disease; Corpus Striatum; Disease Models, Animal; | 2002 |
Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation.
Topics: Age Factors; Animals; Basal Ganglia Diseases; Convulsants; Corpus Striatum; Disease Models, Animal; | 2002 |
The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity.
Topics: Adenosine; Animals; Behavior, Animal; Binding, Competitive; Body Weight; Cerebral Cortex; Corpus Str | 2002 |
Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Diseas | 2002 |
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Can | 2003 |
Increased neuronal hypoxic tolerance induced by repetitive chemical hypoxia.
Topics: Adaptation, Physiological; Animals; Cell Hypoxia; Disease Models, Animal; Hippocampus; Huntington Di | 2002 |
Neuroprotective effects of (+/-)-huprine Y on in vitro and in vivo models of excitoxicity damage.
Topics: Aminoquinolines; Animals; Binding, Competitive; Calcium; Cell Death; Cells, Cultured; Cerebellum; Co | 2003 |
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons.
Topics: Animals; Apoptosis; Cell Nucleus; Cell Survival; Cells, Cultured; Cerebral Cortex; Disease Models, A | 2003 |
Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain; Disease Models, Anim | 2003 |
The effect on motor cortical neuronal development of focal lesions to the sub-cortical white matter in the neonatal rat: a model for periventricular leukomalacia.
Topics: Animals; Animals, Newborn; Apoptosis; Axons; Disease Models, Animal; Humans; Ibotenic Acid; Infant, | 2003 |
Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dependovirus; Disease Models, Animal; Genetic Therapy; G | 2003 |
Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease.
Topics: Acute Disease; Animals; Calpain; Caspases; Cell Death; Chronic Disease; Corpus Striatum; Disease Mod | 2003 |
A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists.
Topics: Adenosine; Animals; Body Weight; Cell Death; Corpus Striatum; Disease Models, Animal; Drug Administr | 2003 |
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
Topics: Acetylation; Animals; Body Weight; Brain; Butyrates; Disease Models, Animal; Dose-Response Relations | 2003 |
MPTP potentiates 3-nitropropionic acid-induced striatal damage in mice: reference to striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Count; Corpus Striatum | 2004 |
Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms.
Topics: Animals; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-Associated Death Protein; Ca | 2004 |
Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caudate Nucleus; Cell Count; Cerebral Cortex; | 2004 |
Mitochondrial calcium, oxidative stress and apoptosis in a neurodegenerative disease model induced by 3-nitropropionic acid.
Topics: Animals; Antioxidants; Apoptosis; Astrocytes; Behavior, Animal; Calcium; Cell Survival; Cells, Cultu | 2004 |
Experimental basis for the putative role of GluR6/kainate glutamate receptor subunit in Huntington's disease natural history.
Topics: Age of Onset; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; | 2004 |
3-Nitropropionic acid-induced neurotoxicity--assessed by ultra high resolution positron emission tomography with comparison to magnetic resonance spectroscopy.
Topics: Acute Disease; Animals; Behavior, Animal; Body Weight; Brain; Choline; Chronic Disease; Disease Mode | 2004 |
Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.
Topics: Animals; Cells, Cultured; Convulsants; Corpus Striatum; Disease Models, Animal; Female; Huntington D | 2004 |
The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism.
Topics: Animals; Cell Death; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Farnesol; Huntingto | 2004 |
3-nitropropionic acid model of metabolic stress: assessment by magnetic resonance imaging.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Magnetic Resonance Imaging; Male; Nitro | 2005 |
Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease.
Topics: Animals; Antioxidants; Brain; Disease Models, Animal; Huntington Disease; Lipid Peroxidation; Male; | 2004 |
FK506 prevents mitochondrial-dependent apoptotic cell death induced by 3-nitropropionic acid in rat primary cortical cultures.
Topics: Animals; Apoptosis; Caspases; Cell Death; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; | 2004 |
Adenosine A1 receptors and the anticonvulsant potential of drugs effective in the model of 3-nitropropionic acid-induced seizures in mice.
Topics: Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Analysis of Variance; Animals; An | 2005 |
Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo.
Topics: Animals; Autoradiography; Convulsants; Disease Models, Animal; Dopamine; Dronabinol; Drug Administra | 2004 |
Minocycline in phenotypic models of Huntington's disease.
Topics: Animals; Calpain; Caspases; Cell Death; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Do | 2005 |
Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Astrocytes; Disea | 2005 |
Altered distribution of striatal activity-dependent synaptic plasticity in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; Huntington Disease; Immunohisto | 2005 |
Differential effects of sublethal ischemia and chemical preconditioning with 3-nitropropionic acid on protein expression in gerbil hippocampus.
Topics: Adaptation, Physiological; Animals; bcl-X Protein; Blotting, Western; Calcium-Transporting ATPases; | 2005 |
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.
Topics: Animals; Brain Chemistry; Capsaicin; Convulsants; Disease Models, Animal; Dopamine; gamma-Aminobutyr | 2005 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; D | 2006 |
Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Down-R | 2005 |
Mechanisms of hypoxic tolerance in presymptomatic APP23 transgenic mice.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Gene Expression | 2006 |
Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons.
Topics: Acetylcholine; Animals; Behavior, Animal; Cholinergic Fibers; Convulsants; Disease Models, Animal; E | 2006 |
Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
Topics: Animals; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Huntington Disease; Male; | 2005 |
17 beta-Estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats.
Topics: Animals; Apoptosis; Caspase 3; Caspases; Cell Survival; Convulsants; Corpus Striatum; Cytoprotection | 2006 |
Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver.
Topics: Acetylcysteine; Animals; Antioxidants; Chemical and Drug Induced Liver Injury; Citric Acid Cycle; Cy | 2006 |
Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Cell Line; Convulsants; Corpus Striatum; Disease Mo | 2006 |
Transcranial magnetic stimulation attenuates cell loss and oxidative damage in the striatum induced in the 3-nitropropionic model of Huntington's disease.
Topics: Animals; Catalase; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Glutathione; Hun | 2006 |
Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Huntington Disease; Ibuprofen; Male; Neurons; Neur | 2006 |
Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats.
Topics: Animals; Astrocytes; Cells, Cultured; Convulsants; Corpus Striatum; Disease Models, Animal; Dose-Res | 2006 |
Infant mice with glutaric acidaemia type I have increased vulnerability to 3-nitropropionic acid toxicity.
Topics: Animals; Animals, Newborn; Brain; Brain Diseases, Metabolic, Inborn; Disease Models, Animal; Dose-Re | 2006 |
Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease.
Topics: Animals; Apoptosis Regulatory Proteins; Calpain; Cell Death; Corpus Striatum; Disease Models, Animal | 2006 |
Co-regulation of dopamine D1 receptor and uncoupling protein-2 expression in 3-nitropropionic acid-induced neurotoxicity: neuroprotective role of L-carnitine.
Topics: Animals; Body Temperature; Carnitine; Disease Models, Animal; Drug Interactions; Gene Expression Reg | 2006 |
Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glutamic Acid; | 2006 |
Effect of testosterone on oxidative stress and cell damage induced by 3-nitropropionic acid in striatum of ovariectomized rats.
Topics: Androgens; Animals; Cell Death; Corpus Striatum; Disease Models, Animal; Drug Antagonism; Female; Hu | 2007 |
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Cell Count; Cell Death; Corpus Striatum; Cytoprotection; Dependovirus; Disease Models, Anim | 2007 |
Mesenchymal stem cell transplantation accelerates hearing recovery through the repair of injured cochlear fibrocytes.
Topics: Animals; Auditory Threshold; Cochlea; Connexins; Disease Models, Animal; Hearing; Hearing Loss, Sens | 2007 |
Caspase inhibitor facilitates recovery of hearing by protecting the cochlear lateral wall from acute cochlear mitochondrial dysfunction.
Topics: Acoustic Stimulation; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Auditory Threshold; Caspa | 2008 |
Catecholamine exocytosis is diminished in R6/2 Huntington's disease model mice.
Topics: Adrenal Glands; Animals; Brain; Catecholamines; Chromaffin Cells; Convulsants; Disease Models, Anima | 2007 |
IGF-1 exacerbates the neurotoxicity of the mitochondrial inhibitor 3NP in rats.
Topics: Animals; Cell Death; Cell Survival; Convulsants; Corpus Striatum; Disease Models, Animal; Dose-Respo | 2007 |
Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Weight; Cerebral Cortex; Citrate (si)-Synthase | 2008 |
Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways.
Topics: Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Enzyme Activation; Extracellular Sig | 2008 |
Granulocyte-colony stimulating factor attenuates striatal degeneration with activating survival pathways in 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Interactions; Fluoresceins; Gene Expression R | 2008 |
Excitotoxic damage, disrupted energy metabolism, and oxidative stress in the rat brain: antioxidant and neuroprotective effects of L-carnitine.
Topics: Animals; Antioxidants; Brain; Carnitine; Convulsants; Disease Models, Animal; Dose-Response Relation | 2008 |
Rasagiline is neuroprotective in a transgenic model of multiple system atrophy.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dop | 2008 |
Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
Topics: Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Dose-Response Relationship, Drug | 2008 |
Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats.
Topics: Animals; Avoidance Learning; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Histocytoche | 1995 |
Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Functional Laterali | 1995 |
Behavioral pathology induced by repeated systemic injections of 3-nitropropionic acid mimics the motoric symptoms of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Injections, Intraperitoneal; M | 1995 |
NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Male; Nerve Growth Factors; Ni | 1996 |
3-Nitropropionic acid neurotoxicity: visualization by silver staining and implications for use as an animal model of Huntington's disease.
Topics: Animals; Brain; Caudate Nucleus; Coloring Agents; Disease Models, Animal; Dose-Response Relationship | 1997 |
Mitochondrial toxin 3-nitropropionic acid produces startle reflex abnormalities and striatal damage in rats that model some features of Huntington's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Hunting | 1997 |
Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Antineoplastic Agents; Creatine; Creatinin | 1998 |
Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Enzyme Inhibitors; Excitatory Amino Acid Agonists; | 1997 |
Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzazepines; Corpus Striatum; Disease Models, A | 1998 |
Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
Topics: Animals; Cerebral Ventricles; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV | 1998 |
Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemist | 2000 |
Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies.
Topics: Animals; Behavior, Animal; Cell Survival; Convulsants; Disease Models, Animal; Drug Administration R | 2000 |
Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain Mapping; Corpus S | 2000 |
Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease.
Topics: Animals; Brain; Calbindins; Cell Line; Ciliary Neurotrophic Factor; Convulsants; Cricetinae; Disease | 2000 |
3-Nitropropionic acid neurotoxicity in organotypic striatal and corticostriatal slice cultures is dependent on glucose and glutamate.
Topics: Animals; Aspartic Acid; Cells, Cultured; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; D | 2000 |
Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant.
Topics: Animals; Brain; Caspase 1; Crosses, Genetic; Disease Models, Animal; Female; Huntington Disease; Mal | 2000 |
Mice transgenic for the Huntington's disease mutation are resistant to chronic 3-nitropropionic acid-induced striatal toxicity.
Topics: Aging; Animals; Behavior, Animal; Body Weight; Corpus Striatum; Crosses, Genetic; Diabetes Mellitus; | 2000 |
Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area.
Topics: 3T3 Cells; Animals; Axonal Transport; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Colchicine | 2001 |
Orphenadrine prevents 3-nitropropionic acid-induced neurotoxicity in vitro and in vivo.
Topics: Animals; Antihypertensive Agents; Blotting, Western; Body Weight; Cell Survival; Cerebellum; Corpus | 2001 |
Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Prote | 2001 |
Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease.
Topics: Animals; Apoptosis; Calcium; Cell Survival; Cells, Cultured; Convulsants; Disease Models, Animal; Fe | 2000 |
No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy).
Topics: Animals; Apomorphine; Brain Tissue Transplantation; Corpus Striatum; Dextroamphetamine; Disease Mode | 2001 |
The mitochondrial toxin 3-nitropropionic acid induces differential expression patterns of apoptosis-related markers in rat striatum.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Corpus Striatum; Disease Models, Animal; Gene Expres | 2001 |
N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury.
Topics: 2,2'-Dipyridyl; Acute Disease; Animals; Aspartic Acid; Biomarkers; Brain Chemistry; Brain Edema; Bra | 2001 |
Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Huntington Disease; Infusion Pumps; Injections, Su | 2001 |
Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.
Topics: Animals; Basal Ganglia; Cannabinoid Receptor Modulators; Cannabinoids; Convulsants; Disease Models, | 2001 |
Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation.
Topics: Animals; Behavior, Animal; Discrimination Learning; Disease Models, Animal; Gait Disorders, Neurolog | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.
Topics: Animals; Cell Death; Cells, Cultured; Cognition; Corpus Striatum; Disease Models, Animal; Female; Hu | 2001 |
Perseverative behavior underlying attentional set-shifting deficits in rats chronically treated with the neurotoxin 3-nitropropionic acid.
Topics: Animals; Attention; Behavior, Animal; Cognition; Corpus Striatum; Discrimination Learning; Disease M | 2001 |
The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Convulsants; Disease Models, Animal; Drug Synergism; Dyskines | 2002 |
Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Convulsants; Disease Mode | 2002 |
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
Topics: Animals; Brain Mapping; Caudate Nucleus; Cebus; Disease Models, Animal; Frontal Lobe; Humans; Huntin | 2002 |
The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-Jun N-terminal kinase/c-Jun module.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Cells, Cultured; Corpus Striatum; Disease Models | 2002 |
Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration.
Topics: Adenoviridae; Animals; Behavior, Animal; Cell Count; Cell Survival; Cerebral Cortex; Ciliary Neurotr | 2002 |
The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease.
Topics: Animals; Cell Survival; Corpus Striatum; Disease Models, Animal; Entopeduncular Nucleus; Globus Pall | 2002 |
beta-Amyloid neurotoxicity is exacerbated during glycolysis inhibition and mitochondrial impairment in the rat hippocampus in vivo and in isolated nerve terminals: implications for Alzheimer's disease.
Topics: Adenosine Triphosphate; Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; D | 2002 |
Studies on the epidemiology and etiology of moldy sugarcane poisoning in China.
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; China; Disease Models, Animal; Dystonia; Food M | 1992 |